CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Ultragenyx - RARE CFD

    40.08
    3.25%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.13
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Ultragenyx Pharmaceutical Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 38.82
    Open* 38.47
    1-Year Change* 6.18%
    Day's Range* 38.47 - 40.08
    52 wk Range 31.52-54.98
    Average Volume (10 days) 750.97K
    Average Volume (3 months) 19.78M
    Market Cap 3.19B
    P/E Ratio -100.00K
    Shares Outstanding 82.11M
    Revenue 410.21M
    EPS -8.98
    Dividend (Yield %) N/A
    Beta 0.73
    Next Earnings Date Feb 14, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 40.08 1.62 4.21% 38.46 40.08 38.46
    Nov 30, 2023 38.82 -0.27 -0.69% 39.09 40.20 37.90
    Nov 29, 2023 39.06 0.64 1.67% 38.42 39.75 38.42
    Nov 28, 2023 38.39 0.22 0.58% 38.17 38.42 37.17
    Nov 27, 2023 38.55 -0.36 -0.93% 38.91 38.91 37.90
    Nov 24, 2023 39.10 1.27 3.36% 37.83 39.29 37.83
    Nov 22, 2023 38.12 -0.70 -1.80% 38.82 39.38 37.81
    Nov 21, 2023 38.79 0.33 0.86% 38.46 39.95 38.31
    Nov 20, 2023 39.27 -0.69 -1.73% 39.96 40.29 38.24
    Nov 17, 2023 39.90 0.93 2.39% 38.97 40.47 38.43
    Nov 16, 2023 38.88 0.56 1.46% 38.32 39.18 38.04
    Nov 15, 2023 39.04 0.78 2.04% 38.26 39.56 38.04
    Nov 14, 2023 38.23 1.80 4.94% 36.43 38.27 36.43
    Nov 13, 2023 35.28 0.89 2.59% 34.39 35.67 33.97
    Nov 10, 2023 34.85 0.34 0.99% 34.51 35.42 34.20
    Nov 9, 2023 34.91 -1.36 -3.75% 36.27 36.36 34.43
    Nov 8, 2023 36.24 -1.80 -4.73% 38.04 38.08 35.52
    Nov 7, 2023 38.00 0.27 0.72% 37.73 38.38 36.93
    Nov 6, 2023 37.75 -0.74 -1.92% 38.49 39.37 37.51
    Nov 3, 2023 38.79 2.21 6.04% 36.58 39.93 36.58

    Ultragenyx Events

    Time (UTC) Country Event
    Wednesday, February 14, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Release
    Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 363.329 351.406 271.03 103.714 51.495
    Revenue 363.329 351.406 271.03 103.714 51.495
    Total Operating Expense 1012.25 733.143 601.146 527.887 422.868
    Selling/General/Admin. Expenses, Total 278.139 219.982 182.933 161.524 127.724
    Research & Development 702.589 496.853 411.884 357.155 281.698
    Operating Income -648.919 -381.737 -330.116 -424.173 -371.373
    Interest Income (Expense), Net Non-Operating -8.225 -40.135 177.441 26.651 9.542
    Other, Net -44.581 -31.109 -32.684 -1.922 -5.588
    Net Income Before Taxes -701.725 -452.981 -185.359 -399.444 -197.097
    Net Income After Taxes -707.421 -454.025 -186.566 -402.727 -197.611
    Net Income Before Extra. Items -707.421 -454.025 -186.566 -402.727 -197.611
    Net Income -707.421 -454.025 -186.566 -402.727 -197.611
    Income Available to Common Excl. Extra. Items -707.421 -454.025 -186.566 -402.727 -197.611
    Income Available to Common Incl. Extra. Items -707.421 -454.025 -186.566 -402.727 -197.611
    Diluted Net Income -707.421 -454.025 -186.566 -402.727 -197.611
    Diluted Weighted Average Shares 69.9142 67.7955 60.8456 56.5769 49.7752
    Diluted EPS Excluding Extraordinary Items -10.1184 -6.69697 -3.06622 -7.11823 -3.97007
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -10.1184 -6.69697 -3.06622 -7.11823 -6.19425
    Cost of Revenue, Total 28.32 16.008 6.129 9.008 1.146
    Gross Profit 335.009 335.398 264.901 94.706 50.349
    Total Extraordinary Items
    Dilution Adjustment
    Depreciation / Amortization 3.2 0.3 0.2 0.2 12.3
    Gain (Loss) on Sale of Assets 0 170.322
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 108.309 100.496 103.348 90.703 89.343
    Revenue 108.309 100.496 103.348 90.703 89.343
    Cost of Revenue, Total 9.914 12.257 5.319 8.631 8.27
    Gross Profit 98.395 88.239 98.029 82.072 81.073
    Total Operating Expense 256.266 254.601 248.976 315.769 230.936
    Selling/General/Admin. Expenses, Total 81.403 76.646 72.849 69.841 68.137
    Research & Development 164.949 165.698 170.808 237.297 154.529
    Operating Income -147.957 -154.105 -145.628 -225.066 -141.593
    Interest Income (Expense), Net Non-Operating 6.225 5.956 8.038 1.857 -9.285
    Other, Net -17.364 -15.328 -15.694 -15.61 -6.982
    Net Income Before Taxes -159.096 -163.477 -153.284 -238.819 -157.86
    Net Income After Taxes -159.828 -163.972 -151.833 -245.106 -158.162
    Net Income Before Extra. Items -159.828 -163.972 -151.833 -245.106 -158.162
    Net Income -159.828 -163.972 -151.833 -245.106 -158.162
    Income Available to Common Excl. Extra. Items -159.828 -163.972 -151.833 -245.106 -158.162
    Income Available to Common Incl. Extra. Items -159.828 -163.972 -151.833 -245.106 -158.162
    Diluted Net Income -159.828 -163.972 -151.833 -245.106 -158.162
    Diluted Weighted Average Shares 70.898 70.3685 70.1548 70.0542 69.9254
    Diluted EPS Excluding Extraordinary Items -2.25434 -2.33019 -2.16426 -3.49881 -2.26187
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -2.25434 -2.33019 -2.16426 -3.49881 -2.26187
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 883.899 856.604 1295.3 851.017 522.369
    Cash and Short Term Investments 747.762 740.196 1201.53 755.23 459.706
    Cash & Equivalents 132.944 307.584 713.526 433.584 113.432
    Short Term Investments 614.818 432.612 488.007 321.646 346.274
    Prepaid Expenses 68.064 71.745 46.783 51.236 42.587
    Other Current Assets, Total 0.862 0 10.847 0.161 0.271
    Total Assets 1545.44 1522.4 1759.56 1135.5 719.558
    Property/Plant/Equipment, Total - Net 285.687 176.183 114.039 74.676 20.046
    Property/Plant/Equipment, Total - Gross 349.068 226.221 151.431 100.664 38.252
    Accumulated Depreciation, Total -63.381 -50.038 -37.392 -25.988 -18.206
    Long Term Investments 154.501 293.858 165.881 32.926 0
    Other Long Term Assets, Total 16.846 20.558 8.812 3.471 3.514
    Total Current Liabilities 261.21 181.368 189.609 103.3 74.725
    Accounts Payable 43.274 17.138 12.923 12.871 12.275
    Accrued Expenses 216.274 156.053 117.007 90.429 62.45
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.479 7.609 59.219
    Total Liabilities 1192.95 599.836 605.18 481.732 110.65
    Total Long Term Debt 0 0.41 0.701 0 0
    Other Liabilities, Total 900.073 384.752 381.564 345.126 4.759
    Total Equity 352.494 922.561 1154.38 653.764 608.908
    Preferred Stock - Non Redeemable, Net 0 0
    Common Stock 0.07 0.069 0.067 0.058 0.051
    Additional Paid-In Capital 3140.02 2997.5 2773.2 2086.86 1639.77
    Retained Earnings (Accumulated Deficit) -2781.02 -2073.6 -1619.58 -1433.01 -1030.28
    Unrealized Gain (Loss) -5.728 -1.283 0.26 0.159 -0.304
    Other Equity, Total -0.845 -0.121 0.429 -0.306 -0.329
    Total Liabilities & Shareholders’ Equity 1545.44 1522.4 1759.56 1135.5 719.558
    Total Common Shares Outstanding 70.1973 69.345 66.8185 57.8382 50.8606
    Total Receivables, Net 40.445 28.432 23.093 32.844 12.74
    Accounts Receivable - Trade, Net 40.445 28.432 23.093 32.844 12.74
    Total Inventory 26.766 16.231 13.048 11.546 7.065
    Goodwill, Net 44.406 44.406 44.406 44.406 44.406
    Intangibles, Net 160.105 130.788 131.113 129 129.223
    Deferred Income Tax 31.667 33.306 33.306 33.306 31.166
    Current Port. of LT Debt/Capital Leases 0.183 0.568 0.46
    Capital Lease Obligations 0 0.41 0.701
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 599.188 702.137 766.336 883.899 1012.67
    Cash and Short Term Investments 442.094 551.981 629.354 747.762 888.675
    Cash & Equivalents 72.575 102.059 85.768 132.944 391.651
    Short Term Investments 369.519 449.922 543.586 614.818 497.024
    Total Receivables, Net 79.263 70.523 42.991 40.445 31.164
    Accounts Receivable - Trade, Net 79.263 70.523 42.991 40.445 31.164
    Total Inventory 31.802 28.256 26.616 26.766 21.849
    Prepaid Expenses 44.053 49.681 65.411 68.064 70.463
    Other Current Assets, Total 1.976 1.696 1.964 0.862 0.517
    Total Assets 1238.14 1311.31 1383.4 1545.44 1618.47
    Property/Plant/Equipment, Total - Net 323.238 308.212 300.822 285.687 263.365
    Goodwill, Net 44.406 44.406 44.406 44.406 44.406
    Intangibles, Net 157.302 158.237 159.171 160.105 158.401
    Long Term Investments 86.11 71.829 90.41 154.501 121.349
    Other Long Term Assets, Total 27.896 26.489 22.259 16.846 18.285
    Total Current Liabilities 253.978 244.379 218.179 261.21 227.361
    Accounts Payable 33.357 42.115 58.981 43.274 23.533
    Accrued Expenses 190.689 178.54 155.665 216.457 200.87
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 29.932 23.724 3.533 1.479 2.958
    Total Liabilities 1206.43 1182.28 1162.92 1192.95 1149.65
    Total Long Term Debt 0 0 0 0 0
    Deferred Income Tax 31.667 31.667 31.667 31.667 33.306
    Other Liabilities, Total 920.781 906.234 913.077 900.073 888.978
    Total Equity 31.714 129.03 220.481 352.494 468.829
    Common Stock 0.072 0.071 0.071 0.07 0.07
    Additional Paid-In Capital 3298.36 3236.88 3169.37 3140.02 3108.17
    Retained Earnings (Accumulated Deficit) -3264.47 -3104.82 -2944.99 -2781.02 -2629.19
    Unrealized Gain (Loss) -1.587 -2.69 -3.266 -5.728 -8.89
    Other Equity, Total -0.657 -0.408 -0.701 -0.845 -1.332
    Total Liabilities & Shareholders’ Equity 1238.14 1311.31 1383.4 1545.44 1618.47
    Total Common Shares Outstanding 72.1659 71.457 70.6524 70.1973 70.0798
    Preferred Stock - Non Redeemable, Net
    Current Port. of LT Debt/Capital Leases
    Capital Lease Obligations
    Treasury Stock - Common -0.381 -0.381 -0.356
    ESOP Debt Guarantee 0.381 0.381 0.356
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -707.421 -454.025 -186.566 -402.727 -197.611
    Cash From Operating Activities -380.465 -338.695 -132.22 -345.383 -290.566
    Cash From Operating Activities 18.22 13.239 12.261 8.539 19.538
    Deferred Taxes -1.639 0 2.14 0
    Non-Cash Items 248.501 165.327 -62.578 64.748 -87.703
    Changes in Working Capital 61.874 -63.236 104.663 -18.083 -24.79
    Cash From Investing Activities -291.652 -195.372 -179.121 -13.039 -33.331
    Capital Expenditures -146.123 -73.093 -43.905 -24.832 -4.076
    Other Investing Cash Flow Items, Total -145.529 -122.279 -135.216 11.793 -29.255
    Cash From Financing Activities 501.208 118.552 600.272 679.306 336.853
    Financing Cash Flow Items 490.395 -0.492 -0.236 314.234 0
    Issuance (Retirement) of Stock, Net 10.813 119.044 600.508 365.072 336.853
    Issuance (Retirement) of Debt, Net 0 0
    Foreign Exchange Effects -1.075 -1.194 1.119 -0.165 -0.472
    Net Change in Cash -171.984 -416.709 290.05 320.719 12.484
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -163.972 -707.421 -555.588 -310.482 -152.32
    Cash From Operating Activities -156.867 -380.465 -290.123 -194.778 -117.521
    Cash From Operating Activities 5.236 18.22 13.263 8.569 4.088
    Non-Cash Items 40.233 248.501 213.815 90.914 42.4
    Changes in Working Capital -38.364 61.874 38.387 16.221 -11.689
    Cash From Investing Activities 111.304 -291.652 -120.053 41.806 -37.362
    Capital Expenditures -25.034 -146.123 -119.153 -93.107 -62.184
    Other Investing Cash Flow Items, Total 136.338 -145.529 -0.9 134.913 24.822
    Cash From Financing Activities -0.722 501.208 499.326 7.449 1.612
    Financing Cash Flow Items 0.028 490.395 490.514 -0.289 -0.143
    Issuance (Retirement) of Stock, Net -0.75 10.813 8.812 7.738 1.755
    Foreign Exchange Effects 0.211 -1.075 -2.427 -1.346 -0.108
    Net Change in Cash -46.074 -171.984 86.723 -146.869 -153.379
    Issuance (Retirement) of Debt, Net
    Deferred Taxes -1.639
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.9011 7236523 231611 2023-08-31 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 6.6484 5405089 1134093 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 6.3685 5177521 76374 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.639 3771480 136076 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 4.3483 3535142 69828 2023-06-30 LOW
    Kakkis (Emil D) Individual Investor 3.4006 2764681 0 2023-10-19 LOW
    ClearBridge Investments, LLC Investment Advisor/Hedge Fund 3.3989 2763246 62169 2023-06-30 LOW
    Sands Capital Management, LLC Investment Advisor 3.2887 2673638 2647289 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.0326 2465450 -280257 2023-06-30 LOW
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 2.1853 1776600 -749000 2023-06-30 LOW
    Alkeon Capital Management LLC Investment Advisor/Hedge Fund 1.9994 1625490 72500 2023-06-30 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.862 1513767 84353 2023-06-30 LOW
    Rock Springs Capital Management LP Hedge Fund 1.7027 1384269 47868 2023-06-30 LOW
    First Trust Advisors L.P. Investment Advisor 1.4205 1154836 -57780 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3046 1060613 45973 2023-06-30 LOW
    Capital International Investors Investment Advisor 1.1899 967357 -327203 2023-06-30 LOW
    Marshall Wace LLP Investment Advisor/Hedge Fund 1.1398 926637 21112 2023-06-30 HIGH
    Avidity Partners Management LP Hedge Fund 1.1079 900700 -1226200 2023-06-30 HIGH
    Two Sigma Investments, LP Hedge Fund 1.1 894274 -91982 2023-06-30 HIGH
    Emerald Advisers LLC Investment Advisor 1.0812 879012 -113265 2023-09-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Ultragenyx Company profile

    About Ultragenyx Pharmaceutical Inc

    Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.

    Equity composition

    Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.

    Industry: Bio Therapeutic Drugs

    60 Leveroni Ct
    NOVATO
    CALIFORNIA 94949
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    XRP/USD

    0.62 Price
    +0.250% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    38,841.75 Price
    -0.020% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading